Early decreases in CD90-positive circulating tumor cells after therapy initiation were associated with tumor shrinkage and longer progression-free survival in both groups, as well as prolonged overall survival in the atezolizumab plus bevacizumab group. This evidence concerns the gene THY1 and neoplasm.